Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

Completed · Not applicable

Conditions studied: Chronic Kidney Diseases, Type 2 Diabetes

In brief

The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.

Key facts

Study ID

NCT02608177

Run by

University of Washington

People needed

3

Starts

2015-11-01

Expected to finish

2018-08-01

Last updated by the study team

2018-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes
• eGFR 15-59 mL/min/1.73 m2
• Hemoglobin A1c < 8%
• Age ≥ 18 years
• Current use of sulfonylurea

You may not qualify if…

• BMI > 40 kg/m2
• Actively using CGM for clinical care
• End stage renal disease needing dialysis
• Kidney transplant
• Pregnant or nursing
• Unable to provide informed consent

Where it is running

• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.